SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Relugolix (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms SPIRIT 1
- Sponsors Myovant Sciences
- 28 Jun 2017 Status changed from planning to not yet recruiting.
- 07 May 2017 According to a Myovant Sciences media release, Company plans to initiate this trial in the second quarter of 2017.
- 01 Mar 2017 According to a Myovant Sciences media release, Company plans to initiate this trial in the first half of 2017.